Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) and Atreca (NASDAQ:BCEL – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Sensei Biotherapeutics and Atreca's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Sensei Biotherapeutics and Atreca, as provided by MarketBeat.com.

Institutional & Insider Ownership

21.3% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 45.2% of Atreca shares are held by institutional investors. 19.9% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 9.6% of Atreca shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Risk and Volatility

Sensei Biotherapeutics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the S&P 500. Comparatively, Atreca has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500.

Earnings & Valuation

This table compares Sensei Biotherapeutics and Atreca's gross revenue, earnings per share and valuation.

Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than Atreca, indicating that it is currently the more affordable of the two stocks.

About Sensei Biotherapeutics

(Get Rating)

Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

About Atreca

(Get Rating)

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.